World's First Nasdaq listed Nature-Derived Psilocybin Biopharma arrives on Wall Street. Thank you Nasdaq for welcoming Psyence Biomedical Ltd (NASDAQ:PBM) #FollowThePsyence
Psyence Biomedical Ltd
Research Services
Psyence Biomed is the World's First NASDAQ-listed Nature-Derived Psilocybin Biopharma
About us
Psyence Biomed Ltd., is a pharmaceutical life science biotechnology company traded on the NASDAQ (NASDAQ:PBM), with a focus on botanical psychedelics. Psyence Biomed is the first Nasdaq-listed nature-derived psilocybin biopharma in the world. The name “Psyence” combines the words “psychedelics” and “science” to affirm our commitment to an evidence-based approach to innovative biopharma. Patient-centered, our physician-led company is led by R+D leader CEO Dr. Neil Maresky, MD, who while working at the intersection of medicine, commerce, and science has brought some 50 medicines to market at AstraZeneca, Wyeth, Bayer, and elsewhere. Psyence Biomed is working to develop an FDA-approved pharmaceutical botanical psilocybin for the treatment of oncology patients diagnosed with Adjustment Disorder in a palliative care context to treat psychosocial distress. Our Phase IIb trials have received ethics approval and begin enrolling patients in this quarter.
- Website
-
https://psyencebiomed.com/
External link for Psyence Biomedical Ltd
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Toronto
- Type
- Public Company
- Founded
- 2023
- Specialties
- Psilocybin and Palliative Care Research
Locations
-
Primary
Get directions
Toronto , CA
Employees at Psyence Biomedical Ltd
Updates
-
From Ibogaine to Ethics, Psyence Biomedical Ltd welcomes this Global Wellness Institute trends update reported by our Washington, D.C.-based Chief of Global Impact, Mary-Elizabeth Gifford.
The nonprofit Global Wellness Institute has published its Top 5 Trends in Psychedelics, an annual report from the Psyence Biomedical Ltd Chief of Global Impact, Mary-Elizabeth Gifford, who chairs the Institute’s Psychedelics & Healing Initiative, which counts Multidisciplinary Association for Psychedelic Studies (MAPS) Rick Doblin as its Honorary Chair. TREND 1: Washington, D.C., the new Psychedelic Capital TREND 2: Make Ibogaine Great Again TREND 3: Ethics & Safety TREND 4: Psychedelics for Active Duty Military and Veteran Health TREND 5: Big is Back: Big Pharma & Big Vision (For full text 5 trends, please see link below) Spotting the 5 top trends in psychedelic medicine needs “no crystal ball,” according to Mary-Elizabeth, who instead credits “the insight generously shared over the last year by psychedelic medicine thought leaders, business leaders, journalists, and advocates." In addition to Mary-Elizabeth's leadership as chair of the Psychedelics & Healing Initiative and on the founding launch team of Psyence Biomedical Ltd, --the first biopharma with a focus on non-synthetic psilocybin to list on Nasdaq-- Mary-Elizabeth is co-author of the Nature vs. Synthetic Psilocybin chapter of the Springer Nature textbook on therapeutic mushrooms. Her original research on psychedelic medicine & trauma was recently cited by the Journal of the American Academy of Psychotherapists in its special issue on "Psychedelics: Healing & Transformation." She is a contributing writer for Lucid News, Inc. A collaborative voice for Psyence Biomedical Ltd on Capitol Hill and elsewhere, she has been named a "Psychedelic Titan" by Microdose Psychedelic Insights; Spirituality & Health Magazine describes Mary-Elizabeth as "the most quietly influential woman working in psychedelics today." https://lnkd.in/e3xAF6tM
-
Why ibogaine? Journalist Rowan Dunne shares an update: “By combining our manufacturing expertise with Psyence Biomedical Ltd's clinical development capabilities, we are creating a powerful platform to explore the full potential of ibogaine and psilocybin in addressing addiction and mental health disorders,” PsyLabs chief executive, Tony Budden, said. Alongside companies like Compass Pathways (NASDAQ: CMPS), atai Life Sciences (NASDAQ: ATAI) (ETR: 9VC), MindMed (Mind Medicine) Inc (NASDAQ: MNMD) and GH Research plc (NASDAQ: GHRS) (FRA: 1KA), Psyence is one of the few psychedelic drug developers listed on the Nasdaq Exchange." And the only biopharma working to develop safe, responsible, FDA-approved candidates with a focus on nature-derived psilocybin and ibogaine. . . https://lnkd.in/edv6KB3X
-
What happens when nature-derived Ibogaine meets Wall Street? Adam Jackson in this issue of the Crain Communications publication Green Market Report shares how Psyence Biomedical Ltd, recognized for its achievement as first biopharma with a non-synthetic psilocybin pharmaceutical candidate to list on Nasdaq, now includes Ibogaine in its nature-derived psychedelic portfolio. https://lnkd.in/erXGs6yz
-
Another first from Psyence Biomedical Ltd https://lnkd.in/eMmYhVG2
Latest Psilocybin Stock News | Top Psychedelic Stocks to Watch Now | Psyence Biomedical | PBM Stock
https://www.youtube.com/
-
Nature-derived Ibogaine meets Wall Street. In another first achieved by Psyence Biomedical Ltd, the first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to list on the Nasdaq, now includes Ibogaine in its focus. Today it was announced that Psyence Biomedical Ltd secured a right of first refusal to acquire the exclusive rights to a dedicated supply of Ibogaine for evaluation in the treatment of SUD, including Alcohol Use Disorder (AUD). This exclusive partnership further strengthens Psyence Biomedical Ltd's integrated development strategy, explains CEO Dr. Neil Maresky ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline and diversification into multiple therapeutic areas. Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a novel approach to addiction treatment. Psyence Biomedical Ltd is one of the world's few vertically integrated biopharmas with a focus on developing FDA-approved psychedelic-based pharmaceutical therapeutics.
-
Please join our management team today for our live webinar. https://lnkd.in/eh86tupR
Sign-ups now being accepted for Psyence Biomedical Ltd's webinar planned for next Thursday, April 10, when the leadership team takes questions and shares insights and answers about this vertically integrated Nasdaq-listed psychedelic biopharma. https://lnkd.in/eZHtpixB
-
-
Sending appreciation to the team at BioSpace for sharing our update, join our leadership team this Thursday for an update and briefing on what's next for the Southern Star Research and Psyence Biomedical Ltd collaboration To register, please visit: https://lnkd.in/e7jF5vsK
-
Psyence Biomedical Ltd is at the table in Washington, D.C., where our Chief of Global Impact, Mary-Elizabeth Gifford supports the Psychedelic Caucus bipartisan leadership: from left to right, Mary-Elizabeth Gifford, Rep Lou Correa (D-Calif), Sen. Tom Daschle The Daschle Group, & U.S. Marine Corp Gen. Rep. Jack Bergman (R-Mich). Congratulations to the Caucus on introducing its first legislation: the Innovative Therapies Centers of Excellence Act. Image courtesy of Congressman Lou Correa's Instagram.
-